苏州玉森

Suzhou Yusen New Drug Development is a Chinese biopharmaceutical company dedicated to the modernization of Traditional Chinese Medicine (TCM) through the development of innovative botanical drugs. The company's lead product, Sangzhi Total Alkaloids (YS-101), was approved by the NMPA in 2020 as a first-in-class treatment for type 2 diabetes, marking a major milestone in TCM-based drug discovery. Yusen focuses on identifying active chemical groups from natural sources and validating them through rigorous clinical trials. Their research pipeline primarily targets metabolic diseases, hyperlipidemia, and gastrointestinal disorders. The company is headquartered in the Suzhou Industrial Park and collaborates with leading academic institutions to advance natural product pharmacology.